Drew Heiple, MD
Nephrology · Russellville, ARNPI 1376665646
Payments from drug & device makers
Across 542 payments — averaging $436.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$162K
- Novo Nordisk$66K
- Amgen$3K
- Mozarc Medical US LLC$2K
- Travere Therapeutics, Inc.$634
- Bayer$444
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$207,50388%
- Travel & lodging$18,4958%
- Food & beverage$9,9574%
- Education$5090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 264 | $161,876 |
| Novo Nordisk | 54 | $66,331 |
| Amgen(2 entities) | 57 | $3,453 |
| Mozarc Medical US LLC | 10 | $1,585 |
| Travere Therapeutics, Inc. | 33 | $634 |
| Bayer | 28 | $444 |
| Vifor Pharma, Inc. | 13 | $278 |
| Medtronic | 4 | $264 |
| Fresenius USA Marketing, Inc. | 11 | $217 |
| Novartis | 11 | $213 |
| Mallinckrodt Hospital Products Inc. | 10 | $198 |
| Ardelyx, Inc. | 7 | $171 |
| Calliditas Therapeutics US Inc. | 6 | $115 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| Aurinia Pharma U.S., Inc. | 6 | $105 |
| Bard Peripheral Vascular, Inc. | 1 | $104 |
| Akebia Therapeutics Inc | 4 | $77 |
| GSK | 3 | $59 |
| Boehringer Ingelheim | 3 | $50 |
| Scpharmaceuticals Inc. | 3 | $47 |
| Cormedix Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Boston Scientific | 2 | $30 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$236,464 in reported general payments places this provider in the 95th percentile of 85 nephrology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 194 | $145,202 |
| VelphoroSucroferric Oxyhydroxide | 36 | $93,206 |
| OzempicSemaglutide | 41 | $48,682 |
| JardianceEmpagliflozin | 41 | $27,680 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $25,647 |
| ProsolParenteral Amino Acid 20% No.1 | 117 | $22,302 |
| Sevelamer Carbonate | 59 | $18,021 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $13,753 |
| XareltoRivaroxaban | 12 | $10,726 |
| NexiumEsomeprazole Magnesium | 12 | $7,226 |
| Calcium Acetate | 45 | $2,259 |
| Bumetanide | 45 | $2,047 |
| Potassium Chloride | 42 | $1,432 |
| Clonidine | 15 | $1,373 |
| Nifedipine ErNifedipine | 64 | $1,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Nexium | $161,876 | $178,076243 claims |
| Fresenius USA Marketing, Inc.Velphoro | $217 | $93,20636 claims |
| Novo NordiskOzempic | $66,331 | $48,68241 claims |
| Boehringer IngelheimJardiance | $50 | $27,68041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 85 nephrology providers in Arkansas.
Other nephrology in Russellville
- Muhammad KashifPine Bluff$160K
- Luis JuncosLittle Rock$124K
- Clinton EdwardsJonesboro$111K
- Steven WrightPine Bluff$103K
- Dumitru RotaruFort Smith$99K
- Nithin KarakalaLittle Rock$56K
- Fatima AyubLittle Rock$48K
- John HeifnerLittle Rock$46K
- Srilakshmi RavulaLittle Rock$35K
- Nadia AlquriniLittle Rock$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.